Back

Yuhan target price implies 39.4% upside as lazertinib prescriptions expand

Verifying
  • Yuhan’s growth outlook centers on broader lazertinib prescriptions and resigercept licensing prospects.
  • 39.4% upside separates Heungkuk Securities’ 110,000-won target from Yuhan’s 78,900-won close.
  • Heungkuk Securities retained its buy rating on Yuhan in its report on the 11th.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
Yuhan target price implies 39.4% upside as lazertinib prescriptions expand - CoinPost Terminal